#United States #New York #Securities Fraud #Pomerantz Law #Vistagen

Investor Alert: Class Action Lawsuit on Vistagen Therapeutics

The Pomerantz Law Firm, recognized for its dedication to protecting investors, has recently announced the initiation of a class action lawsuit concerning Vistagen Therapeutics, Inc. (NASDAQ: VTGN). This lawsuit is primarily focused on investors who may have suffered losses due to alleged fraudulent activities associated with the company.

Understanding the Lawsuit

This class action highlights serious allegations against Vistagen and certain members of its executive team regarding potential securities fraud and other unlawful business practices. Investors who purchased Vistagen securities during the class period—defined in this case as the time leading up to December 17, 2025—are particularly encouraged to come forward. They have until March 16, 2026, to request appointment as Lead Plaintiff in the class action, which is a key step in holding the company accountable for its alleged missteps.

The catalyst for this litigation arose from a troubling announcement made by Vistagen on December 17, 2025. The company revealed that its PALISADE-3 Phase 3 study, which evaluated the efficacy of intranasal fasedienol for treating social anxiety disorder, did not meet its primary endpoint. Specifically, the treatment showed no significant improvement over a placebo in the measures used to evaluate its effectiveness. Following this announcement, Vistagen's stock plummeted dramatically, dropping $3.499 per share—or an astonishing 80.25%—to a closing price of just $0.861 per share on the same day.

The Implications for Investors

The steep decline in stock prices not only reflects market sentiment but also raises numerous questions about the company’s disclosures and operational transparency. Investors who feel they have been misled by Vistagen's previous communications are now encouraged to contact Pomerantz LLP for assistance in exploring their legal options. The law firm has laid out clear contact information for those seeking to engage in the class action, including an email avenue and a dedicated telephone line.

Pomerantz Law Firm: A Legacy of Advocacy

Founded by the renowned civil litigator Abraham L. Pomerantz, the Pomerantz Law Firm has been at the forefront of securities class actions for more than 85 years. Known as the “dean of the class action bar,” Pomerantz pioneered efforts to protect investors against corporate malfeasance. The firm has earned a reputation for its relentless pursuit of justice, having secured significant damages for countless investors who have been wronged by corporations. This legacy continues as they represent those affected by the alleged fraud at Vistagen.

Next Steps for Affected Investors

For any investor who has purchased shares of Vistagen Therapeutics during the specified period and believes they have incurred losses, timely action is crucial. Engaging with Pomerantz LLP as soon as possible to express interest in the class action could be the first step towards obtaining restitution for losses incurred. Investors are urged to provide their mailing address, phone number, and details of the shares they purchased when reaching out to the firm.

As this case unfolds, it serves as a stark reminder of the volatile nature of the biotech sector and the risks investors face, especially when dealing with companies in the early stages of drug development.

For further information, potential plaintiffs are advised to review the specifics of the Complaint available on the firm’s website or through their direct inquiries. This situation could develop rapidly, and staying informed will be essential for all involved.